Item
Panosa Roqueta, Clara
Tebar, Francesc Ferrer-Batallé, Montserrat Fonge, Humphrey Seno, Masaharu Reilly, Raymond M Massaguer i Vall-llovera, Anna Llorens Duran, Rafael de |
|
2018 June 5 | |
The members of the epidermal growth factor (EGF)/ErbB family are prime targets for cancer therapy. However, the therapeutic efficiency of the existing anti-ErbB agents is limited. Thus, identifying new molecules that inactivate the ErbB receptors through novel strategies is an important goal on cancer research. In this study we have developed a shorter form of human EGF (EGFt) with a truncated C-terminal as a novel EGFR inhibitor. EGFt was designed based on the superimposition of the three-dimensional structures of EGF and the Potato Carboxypeptidase Inhibitor (PCI), an EGFR blocker previously described by our group. The peptide was produced in E. coli with a high yield of the correctly folded peptide. EGFt showed specificity and high affinity for EGFR but induced poor EGFR homodimerization and phosphorylation. Interestingly, EGFt promoted EGFR internalization and translocation to the cell nucleus although it did not stimulate the cell growth. In addition, EGFt competed with EGFR native ligands, inhibiting the proliferation of cancer cells. These data indicate that EGFt may be a potential EGFR blocker for cancer therapy. In addition, the lack of EGFR-mediated growth-stimulatory activity makes EGFt an excellent delivery agent to target toxins to tumours over-expressing EGFR | |
http://hdl.handle.net/2072/320366 | |
eng | |
Public Library of Science | |
Attribution 3.0 Spain | |
http://creativecommons.org/licenses/by/3.0/es/ | |
CÃ ncer -- Tractament
Cancer -- Treatment |
|
Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity | |
info:eu-repo/semantics/article | |
Recercat |